Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

More documents

Recommendations

Info

Aplotipo KIR AA HLA-C1/C1 HLA-C1/C2 HLA-C2/C2 13/54 (25,5%) 4/25 8/25 25/47 (53%) 280 7/52 (13,5%) 4/24 9/24 17/52 (33%) 10° CONGRESSO NAZIONALE <strong>SIMIT</strong> 2,04 2,34 5 aKIR 8 13 0,71 Interazioni attivatorie KIR2DS2 – HLA-C1 KIR2DS1 – HLA-C2 I80/I80 KIR3DS1–HLA-Bw4 I80carr KIR3DS1–HLA-Bw4 Interazioni inibitorie KIR2DL1 – HLA-C2 car 25 casi 5/12 6/20 6/54 (11.1%) 6/41 6/19 (31,6%) 14/47 40/51 (78.4%) 24 controlli 7/13 6/16 10/52 (19.2%) 10/45 10/17 (58,6%) 15/52 33/52 (63.5%) 0,61 0,71 0,53 0,6 0,32 2,80 1,58
KIR2DL1 – HLA-C2 car 31/41 (75.6%) 281 29/45 (64.4%) 10° CONGRESSO NAZIONALE <strong>SIMIT</strong> 1,71
Page 1 and 2:
Abstract 230 - IMPIEGO DEI GLICOPEP
Page 3 and 4:
Abstract 223 - VANCOMICINA IN INFUS
Page 5 and 6:
5 10° CONGRESSO NAZIONALE SIMIT Ab
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
11 10° CONGRESSO NAZIONALE SIMIT A
Page 13 and 14:
Azithromycin R 2 Gentamicin S 1 Van
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Abstract 9 - SIEROPREVALENZA DELL
Page 29 and 30:
Page 31 and 32:
Abstract 170 - MALATTIA DI LYME A B
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Abstract 144 - EPIDEMIA DI TRICHINE
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
16 Legati al paziente 4 Non identif
Page 59 and 60:
Page 61 and 62:
Nausea 24 % Rinorrea 21 % Congiunti
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
75 10° CONGRESSO NAZIONALE SIMIT F
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Via di trasmissione TD vs altre 65.
Page 83 and 84:
Abstract 194 - LESIONE EPIGLOTTICA
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
101 10° CONGRESSO NAZIONALE SIMIT
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Genere maschile, n 30 (58%) Età me
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
TAS>51 TAS95%, n (%) 19 (61,3) 13 (
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Abstract 262 - SINDROME DI LYELL IN
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Abstract 117 - POTENZIALITÀ RIPROD
Page 173 and 174:
Abstract 137 - INFEZIONI DA HBV, HC
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Demografiche Comorbidità Sintomi d
Page 193 and 194:
Neisseria Meningitidis S. Pneumonia
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230: 229 10° CONGRESSO NAZIONALE SIMIT
Page 239 and 240: Abstract 55 - EPATITE VIRALE ACUTA
Page 257 and 258: IL28b: CC HCVRNA UI/L, mediana (IQR
Page 263 and 264: Abstract 23 - UN CASO INUSUALE DI I
Page 279: 279 10° CONGRESSO NAZIONALE SIMIT
Page 295 and 296: Abstract 305 - STREPTOCOCCAL SHOCK
Page 307 and 308: Study ID Greif (2000) Pryor (2004)
Page 327 and 328: Abstract 89 327 10° CONGRESSO NAZI
Page 331 and 332:
Abstract 72 - GRAVE QUADRO DI IRIS
Page 333 and 334:
show all

Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?